An inhibitory effect of TZP-4238 on the growth of androgen-sensitive rat prostatic tumor (Dunning R3327).

Abstract

An inhibitory effect of TZP-4238, a newly synthesized antiandrogen, on the growth of Dunning R3327 rat prostatic tumor was studied and compared with that of chlormadinone acetate (CMA). TZP-4238 markedly suppressed the growth of R3327 tumor. The inhibitory effect of TZP-4238 on the tumor was more potent than that on the prostate. While the inhibitory effect of TZP-4238 on the weight of the ventral prostate was about 6 times as great as that of CMA, the suppressive effect of TZP-4238 on tumor weight was about 40 times as great as that of CMA. Serum levels of testosterone and dihydrotestosterone showed no obvious changes after the administration of either TZP-4238 or CMA. The inhibitory effect of TZP-4238 on the growth of R3327 tumor indicated the application of the compound to human prostatic cancer.

• Authors: T Ichikawa, S Akimoto, J Shimazaki
• Journal: Endocrine journal (Endocr J) Vol. 40 Issue 4 Pg. 425-30 (Aug 1993) ISSN: 0918-8959 [Print] Japan
• PMID: 7522799 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Androgen Antagonists
• Androgens
• Dihydrotestosterone
• Chlormadinone Acetate
• Testosterone
• osaterone acetate

Topics

• Administration, Oral
• Androgen Antagonists (administration & dosage, therapeutic use)
• Androgens (metabolism)
• Animals
• Chlormadinone Acetate (administration & dosage, analogs & derivatives, therapeutic use)
• Dihydrotestosterone (blood)
• Male
• Neoplasms, Hormone-Dependent (drug therapy, metabolism, pathology)
• Orchiectomy
• Organ Size (drug effects)
• Prostate (drug effects, pathology)
• Prostatic Neoplasms (drug therapy, metabolism, pathology)
• Rats
• Testis (drug effects, pathology)
• Testosterone (blood)